ReviewCancer research2017
Recommended Guidelines for Validation, Quality Control, and Reporting of
Open access · greenAbstract readReview
In one paragraph
Review in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Guideline
- ComplexInternational journal of molecular sciences · 2026Review
- Regulation of oncogenic C-terminal truncated p53β protein isoform expression by SRSF3-UPF1 splicing and surveillance axis.Cell & bioscience · 2026Article
- First functional evidence that a rare germline TP53β variant drives senescence-associated immune suppression and impairs apoptosis and cell migration in breast cancer patients.Translational oncology · 2026Article
- Clinical Features and Treatment Strategies of Li-Fraumeni Syndrome Patients With Inherited TP53 Mutations.Molecular genetics & genomic medicine · 2026Article
- Article
- Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.Nature genetics · 2025Article
- The importance ofMolecular biology research communications · 2025Review
- Dysregulation of the p53 pathway provides a therapeutic target in aggressive pediatric sarcomas with stem-like traits.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Germline variant affecting p53β isoforms predisposes to familial cancer.Nature communications · 2024Article
- Structural basis of p53 inactivation by cavity-creating cancer mutations and its implications for the development of mutant p53 reactivators.Cell death & disease · 2024Article
- Article
- p53 activation enhances the sensitivity of non-small cell lung cancer to the combination of SH003 and docetaxel by inhibiting de novo pyrimidine synthesis.Cancer cell international · 2024Article
- Germline Genetic Mutations in Adult Patients with Sarcoma: Insight into the Middle East Genetic Landscape.Cancers · 2024Article
- Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy.Cancer communications (London, England) · 2024Review
- Review
- p53 Dysregulation in Breast Cancer: Insights on Mutations in theInternational journal of molecular sciences · 2023Article
- Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.Cancer medicine · 2023Article
- The High Expression of p53 Is Predictive of Poor Survival RatherJournal of oncology · 2023Article
- The splicing factor proline and glutamine rich promotes the growth of osteosarcoma via the c-Myc signaling pathway.American journal of cancer research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 9 institutions in 6 countries.
Bernard LeroySorbonne Université, UPMC Univ Paris 06, Paris, France.
Mandy L BallingerCancer Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Fanny Baran-MarszakHôpital Avicenne, Assistance Publique-Hôpitaux De Paris, Bobigny, Service D'H ematologie Biologique, France.
Gareth L BondLudwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
Antony BraithwaiteDept of Pathology, School of Medicine, University of Otago, Dunedin, New Zealand.
Nicole ConcinDepartment of Gynecology and Obstetrics, Innsbruck Medical University, Innsbruck, Austria.
Lawrence A DonehowerHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas.
Wafik S El-DeiryDepartment of Hematology/Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Pierre FenauxService d'hématologie séniors, Hôpital St Louis/Université Paris 7, 1 avenue Claude Vellefaux, Paris, France.
Gianluca GaidanoDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
Anita LangerødDepartment of Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Eva Hellstrom-LindbergKarolinska Institute, Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska University Hospital, Stockholm, Sweden.
Richard IggoBergonié Cancer Institute University of Bordeaux 229 cours de l'Argonne 33076 Bordeaux, France.
Jacqueline Lehmann-CheMolecular Oncology Unit, Hospital Saint Louis, Paris, France.
Phuong L MaiCancer Genetics Program, Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
David MalkinDivision of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Ute M MollDepartment of Pathology, Stony Brook University, Stony Brook, New York.
Jeffrey N MyersThe University of Texas MD Anderson Cancer Center, Houston, Texas.
Kim E NicholsDepartment of Oncology, Division of Cancer Predisposition, St. Jude Children's Research Hospital, Memphis, Tennessee.
Sarka PospisilovaMasaryk University, CEITEC - Molecular Medicine and University Hospital Brno, Department of Internal Medicine - Hematology and Oncology, Brno, Czech Republic.
Patricia Ashton-ProllaUniversidade Federal do Rio Grande do Sul (UFRGS) e Serviço deGenética Médica-HCPA, Rua Ramiro Barcelos, Porto Alegre, Brasil.
Davide RossiDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
Sharon A SavageClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Louise C StrongThe University of Texas MD Anderson Cancer Center, Houston, Texas.
Patricia N ToninDepartments of Medicine and Human Genetics, McGill University and Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
Robert ZeillingerMolecular Oncology Group, Department of Obstetrics and Gynaecology, Medical University of Vienna, Vienna, Austria.
Thorsten ZenzUniversity of Heidelberg, Department of Medicine V, Heidelberg, Germany; Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center (dkfz), Heidelberg, Germany.
Joseph F FraumeniDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Peter E M TaschnerGenerade Centre of Expertise Genomics and University of Applied Sciences Leiden, Leiden, the Netherlands.
Pierre HainautInstitut Albert Bonniot, Inserm 823, Université Grenoble Alpes, Rond Point de la Chantourne, La Tronche, France.
Thierry SoussiSorbonne Université, UPMC Univ Paris 06, Paris, France. thierry.soussi@ki.se thierry.soussi@upmc.fr.
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USCanada Research Chairs · CAInternational Prevention Research Institute · FRLeiden University · NLNational Cancer Institute · USStony Brook University · USUniversidade Federal do Rio Grande do Sul · BRUniversity of Oxford · GB
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MClinical Genetic Studies of Familial and Hereditary Cancer SyndromesZIACP010144 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SAVAGE, SHARON A. · 2009 to 2025
$111.8MIntramural NIH HHS ZIA CP010144
Abstract
Accurate assessment of
Indexed as
Quality ControlGenetic VariationHumansNeoplasmsPractice Guidelines as TopicTumor Suppressor Protein p53Validation Studies as TopicTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.